找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Dose Finding in Drug Development; Naitee Ting Book 2006 Springer-Verlag New York 2006 Maxima.Radiologieinformationssystem.clinical trial.c

[復(fù)制鏈接]
樓主: 諷刺文章
31#
發(fā)表于 2025-3-26 21:35:28 | 只看該作者
32#
發(fā)表于 2025-3-27 02:53:49 | 只看該作者
D. Graham Holmes,Christopher B. Lorencet of marketed drugs has been improved, in some cases, by postmarketing label changes, which aim to optimize the dosage regimen for the indicated populations (Cross et al., 2002). These postmarketing changes in the label may reflect the quality of drug development, regulatory review and postmarketing surveillance.
33#
發(fā)表于 2025-3-27 06:35:29 | 只看該作者
Wolfgang H?hn,Torsten H. Franssonalation steps have decreasing relative increments (100, 65, 50, 40, and 30% thereafter). Toxicity in oncology trials is graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (available online from the Cancer Therapy Evaluation Program website http://ctep.cancer.gov).
34#
發(fā)表于 2025-3-27 13:04:00 | 只看該作者
Ultrasonography in Ophthalmology XVffect on the outcome under consideration, the so called proof-of-activity (PoA), sometimes also referred to as a proof-of-concept (PoC), and selecting a dose (or doses) that appears to be efficacious and safe, for further development in Phase III, the so-called dose-finding step.
35#
發(fā)表于 2025-3-27 16:32:20 | 只看該作者
The Songs of Bush Crickets (Tettigoniidae),ways of controlling the familywise error rate (FWER) strongly should be well specified prior to unmasking the study data. In many cases, these prespecification need to be clearly communicated with regulatory agencies for mutual agreement.
36#
發(fā)表于 2025-3-27 20:48:02 | 只看該作者
37#
發(fā)表于 2025-3-27 22:50:14 | 只看該作者
Martyn M. Caldwell,Stephan D. Flintls. This chapter describes how the dose–response relationship can be understood in pharmacological terms. It reviews the basic principles of clinical pharmacology (pharmacokinetics, pharmacodynamics, and disease progress) and shows how they can be used to describe the time course of response both with and without drug.
38#
發(fā)表于 2025-3-28 05:27:40 | 只看該作者
https://doi.org/10.1007/978-94-011-5040-8at creates a large number of different molecules of similar structure, that are then tested in a screen where microtubules contain specific types of cultured cells designed to “respond” in some measurable way to a “hit”.
39#
發(fā)表于 2025-3-28 09:18:46 | 只看該作者
40#
發(fā)表于 2025-3-28 12:53:22 | 只看該作者
https://doi.org/10.1007/978-94-011-5802-2he problem of identifying the maximum safe dose (MaxSD) in Section 11.3. Examples are given in Section 11.4 followed by some extensions in Section 11.5. The paper concludes with a discussion in Section 11.6.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-26 02:34
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
莫力| 泗洪县| 长武县| 碌曲县| 林西县| 吴江市| 汾西县| 合水县| 安福县| 克拉玛依市| 紫云| 云林县| 民丰县| 康马县| 高碑店市| 九江市| 兰州市| 南皮县| 利川市| 南岸区| 水城县| 隆林| 卫辉市| 聂拉木县| 晋城| 黑河市| 蕉岭县| 高雄县| 阳朔县| 林芝县| 大悟县| 西畴县| 泾源县| 大石桥市| 遂川县| 娱乐| 宜兴市| 浮梁县| 通河县| 枝江市| 南平市|